Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BETA-TT17
- Development stage
- Preclinical
- Lead developer
- Filamon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BETA-TT17 is an oral, small molecule multi-modal drug candidate developed by Filamon for the treatment of cancer. As part of Filamon's BETA platform, BETA-TT17 acts via the MEK-ERK-AP1 signal transduction and gene transcription pathway, specifically binding to select MEK and ERK proteins to deliver anti-inflammatory, anti-angiogenic, and immuno-oncology functions. It is designed to reduce PD-1 expression by T cells, re-activate CD69+ CD8+ cytotoxic T cells, inhibit major angiogenesis-associated genes (including VEGF, VCAM-1, and ICAM-1), and exert direct cytotoxicity on cancer cells via MAPK pathway inhibition. As of late 2025, BETA-TT17 is in preclinical development, with plans to make the drug clinic-ready in early 2027.
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on BETA-TT17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BETA-TT17.